Future University In Egypt (FUE)

Staff Research

Paper Title :
Author : Hadeer Eid Eliwa
CoAuthors : Ebtissam Darweesh, Nagwa Sabri, Naglaa Bazan
Source : Archives of Pharmaceutical Sciences Ain Shams University
Date of Publication : 07/2020
Abstract : Heart failure (HF) is an epidemic of cardiovascular disease resulting in impaired function and worsened quality of life (QOL) of HF patients. Increased heart rate correlates with poor outcomes in these patients; therefore, its reduction may be beneficial in reducing hospitalization for worsening HF. Guideline therapy recommendation for β-blocking agents is a standard cornerstone for the treatment of HF. Despite, the dose adjustment of β-blockers for patients who cannot withstand the target dose, desired goal heart rate reduction is unfortunately not always reached. Additionally, β-blockers are contraindicated for certain patients. Ivabradine decreases the heart rate through inhibiting the cardiac pacemaker current (If) without having any influence on the sympathetic nervous system. The drug has been approved by the United States Food and Drug Administration in 2015. In 2012, ivabradine use was included in the European Society of Cardiology (ESC) guidelines for the management of HF, to be used alongside β-blockers or as a safer substitute. This short review aimed to discuss the ivabradine use in both reduced and preserved ejection fraction HF patients. Ivabradine was found to be generally tolerable and safe. Efficacy for HF patients with systolic dysfunction has been confirmed, however, in HF patients with diastolic dysfunction, it is yet to be extensively evaluated. Moreover, the role of ivabradine in HF patients with Atrial Fibrillation (AF) is currently under investigation. Keywords: Ivabradine; Heart Failure; Heart Rate; Quality of Lif. *Correspondence | Hadeer E Eliwa; Clinical Pharmacy Department, Faculty of pharmaceutical
Download PDF
BACK
  • Research Centers

    With the growing emphasis on collaborative and interdisciplinary science, Research Centers have become indispensable to highly ranked universities. They gain their importance from the outstanding role they play in enhancing the academic activities, in general, and post graduate reputation and scientific ranking in particular. Realizing this fact, Future University in Egypt (FUE) have decided and allocated sufficient funds and infrastructure to establish FUE Research Center (FUERC) having the following vision, mission, and goals

    read more
  • Continuing Education

    Future University in Egypt’s Department of Continuing Education (DCE) is dedicated to bridging the gap between the capabilities

    read more
  • FUE Pharmaceutical Factory

    The Future Factory for Industrial Training’s (FFIT) aim is to be recognized for its unique training facility as well as its advanced techniques. As a result, we established a training pharmaceutical plant, that provides an actual simulation of an industrial atmosphere with the processes and procedures that take place in the manufacturing world.

    read more
  • FUE Dental Hospital

    FUE has maintained a highly reputable dental faculty over the years, therefore the development of the Dental Hospital is a step towards the FUE goal of providing the best dental academic programs

    read more
Community service unit at Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, launches Q&A about Covid-19.

Community service unit at Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, launches Q&A about Covid-19.

COVID-19 Awareness
FUEscientificJournals

VISIT FUE

Take a step to<br>Future<br>For a better future

Address

End of 90th St., Fifth Settlement,
New Cairo, Egypt

Hotline

Inside Egypt: 16383 (16FUE)

Outside Egypt: +20216383, +2026186100

Copyright © 2023 [Future University in Egypt]. All rights reserved.